Medical Technology

Current search: abbvie

@xconomy.com 9 days ago

Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More

@xconomy.com 18 days ago

Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue

@xconomy.com 23 days ago

Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More

@xconomy.com 1 month ago

AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact

@xconomy.com 6 months ago

Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More

@xconomy.com 8 months ago

Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More

@xconomy.com 9 months ago

Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines

@xconomy.com 11 months ago

Disc Medicine Launches With $50M to Advance New Anemia Treatments

@xconomy.com 1 year ago

Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More

@xconomy.com 1 year ago

Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More

@xconomy.com 1 year ago

Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More

@techcrunch.com 1 year ago

What top VCs look for in women’s fertility startups

@xconomy.com 1 year ago

Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More

@geekwire.com 1 year ago

Seattle startup Rodeo Therapeutics raises more cash for regenerative medicine treatments

@xconomy.com 1 year ago

Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away

@xconomy.com 1 year ago

Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More

@xconomy.com 1 year ago

Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More

@xconomy.com 1 year ago

Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms

@xconomy.com 1 year ago

ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More

@xconomy.com 1 year ago

Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More